References
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. 2015 cited 2022 Jun 1]. Available from 2022 Jun 1: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf
- Lamanna WC, Holzmann J, Cohen HP, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther. 2018;18(4):369–379.
- Agency EM. Guideline on similar biological medicinal products. 2014 cited 2022 Jun 1. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Glob Oncol. 2017;3(5):596–610.
- Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692.
- Amgen. Amgen Xgeva® (Denosumab) prescribing information. cited 2022 Jun 1. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125320s203lbl.pdf
- Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18. Published 2017 May 18.
- Chen Q, Hu C, Liu Y, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose Denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study. PLoS One. 2018;13(6). DOI: 10.1371/journal.pone.0197984.
- Hou J, Hu Z, Xu W, et al. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and Denosumab (Xgeva®) in healthy Chinese subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled clinical study. Int Immunopharmacol. 2022;107:108666.
- Zhang H, Wu M, Zhu X, et al. A phase I, randomized, single-dose study to evaluate the biosimilarity of QL1206 to Denosumab among Chinese healthy subjects. Front Pharmacol. 2020;11:01329.
- Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793–807 .
- Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet. 2012;51(4):247–260.
- Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003;67(9):1959–1966.
- Camponovo C, Aubry-Rozier B, Lamy O, et al. Hypercalcemia upon Denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int. 2020;31(12):2485–2491.
- Makras P, Polyzos SA, Papatheodorou A, et al. Parathyroid hormone changes following Denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013;79(4):499–503.
- Strickling J, Wilkowski MJ. Severe, symptomatic hypocalcemia due to Denosumab administration: treatment and clinical course. Case Rep Nephrol Dial. 2019;9(1):33–41.
- Ferri N, Bellosta S, Baldessin L, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–599.